Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 5Terminated 3Recruiting 2Unknown 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 55NETWORK 10NIH 8OTHER_GOV 3INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Camurati-Engelmann Syndrome 1

Interventions

pembrolizumab 185Carboplatin 129Cisplatin 100Paclitaxel 99Gemcitabine 84Pemetrexed 76durvalumab 75Nivolumab 67Docetaxel 55atezolizumab 52Cyclophosphamide 50Bevacizumab 48Dexamethasone 46Capecitabine 45Oxaliplatin 43Rituximab 40Lenalidomide 40130-nm albumin-bound paclitaxel 39Fluorouracil 38Fulvestrant 37Prednisone 32osimertinib 31olaparib 29Leucovorin 29fludarabine 28venetoclax 27Trastuzumab 27Doxorubicin 27Etoposide 25Cetuximab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × INDUSTRY × Radiotherapy, Intensity-Modulated × Clear all
NCT02937272 2026-04-03

A Study of LY3200882 in Participants With Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
223 enrolled

Camurati-Engelmann Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡